Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 7, 2007 - Issue 4
Submit an article Journal homepage
159
Views
35
CrossRef citations to date
0
Altmetric
Review

Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder

Jud A Staller Associate Professor, Division of Child & Adolescent Psychiatry, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA. [email protected]
&
Stephen V Faraone Director, Medical Genetics Research, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA. [email protected]
Pages 351-362 | Published online: 09 Jan 2014

References

  • Bressan RA, Crippa JA. The role of dopamine in reward and pleasure behaviour – review of data from preclinical research. Acta Psychiatr. Scand.427(Suppl.), 14–21 (2005).
  • Bohnen NI, Cham R. Postural control, gait, and dopamine functions in parkinsonian movement disorders. Clin. Geriatr. Med.22(4), 797–812 vi (2006).
  • Nutt DJ, Demyttenaere K, Janka Z et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J. Psychopharmacol. (2006) [Epub ahead of print].
  • Cristina C, Garcia-Tornadu I, Diaz-Torga G et al. Dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma. Front Horm. Res.35, 50–63 (2006).
  • Brooks DJ. Dopaminergic action beyond its effects on motor function: imaging studies. J. Neurol.253(Suppl. 4), iv8–iv15 (2006).
  • Sevy S, Hassoun Y, Bechara A et al. Emotion-based decision-making in healthy subjects: short-term effects of reducing dopamine levels. Psychopharmacology (Berl.)188(2), 228–235 (2006).
  • King JA, Tenney J, Rossi V, Colamussi L, Burdick S. Neural substrates underlying impulsivity. Ann. NY Acad. Sci.1008, 160–169 (2003).
  • Arnsten AF. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology31(11), 2376–2383 (2006).
  • Faraone S, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry2(2), 104–113 (2003).
  • Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J. Clin. Psychiatry59(Suppl. 7), 4–16 (1998).
  • Kessler RC, Adler L, Barkley R et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am. J. Psychiatry163(4), 716–723 (2006).
  • Ackerman PT, Dykman RA, Oglesby DM, Newton JE. EEG power spectra of children with dyslexia, slow learners, and normally reading children with ADD during verbal processing. J. Learn. Disabil.27(10), 619–630 (1994).
  • Arnsten AF. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J. Clin. Psychiatry67(Suppl. 8), 7–12 (2006).
  • Russell VA, Oades RD, Tannock R et al. Response variability in attention-deficit/hyperactivity disorder: a neuronal and glial energetics hypothesis. Behav. Brain Funct.2, 30 (2006).
  • Todd RD, Botteron KN. Is attention-deficit/hyperactivity disorder an energy deficiency syndrome? Biol. Psychiatry50(3), 151–158 (2001).
  • Valera EM, Faraone SV, Murray KE, Seidman LJ. Meta-Analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol. Psychiatry (2006) [Epub ahead of print].
  • Vaidya CJ, Bunge SA, Dudukovic NM et al. Altered neural substrates of cognitive control in childhood ADHD: evidence from functional magnetic resonance imaging. Am. J. Psychiatry162(9), 1605–1613 (2005).
  • Aron AR, Robbins TW, Poldrack RA. Inhibition and the right inferior frontal cortex. Trends Cogn. Sci.8(4), 170–177 (2004).
  • Sowell ER, Thompson PM, Welcome SE et al. Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Lancet362(9397), 1699–1707 (2003).
  • Leiner HC, Leiner AL. How fibers subserve computing capabilities: similarities between brains and machines. Int. Rev. Neurobiol.41, 535–553 (1997).
  • Leiner HC, Leiner AL, Dow RS. The human cerebro-cerebellar system: its computing, cognitive, and language skills. Behav. Brain Res.44(2), 113–128 (1991).
  • Leiner HC, Leiner AL, Dow RS. Cognitive and language functions of the human cerebellum. Trends Neurosci.16(11), 444–447 (1993).
  • Hoshi E, Tremblay L, Feger J, Carras PL, Strick PL. The cerebellum communicates with the basal ganglia. Nat. Neurosci.8(11), 1491–1493 (2005).
  • Schweighofer N, Doya K, Kuroda S. Cerebellar aminergic neuromodulation: towards a functional understanding. Brain Res. Brain Res. Rev.44(2–3), 103–116 (2004).
  • Barili P, Bronzetti E, Ricci A, Zaccheo D, Amenta F. Microanatomical localization of dopamine receptor protein immunoreactivity in the rat cerebellar cortex. Brain Res.854(1–2), 130–138 (2000).
  • Hallowell EM, Ratey JJ. Driven to Distraction: Recognising and Coping with Attention Deficit Disorder from Childhood Through Adulthood. Touchstone, NY, USA (1994).
  • Greenhill LL, Pliszka S, Dulcan MK et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J. Am. Acad. Child Adolesc. Psychiatry4(Suppl. 2), S26–S49 (2002).
  • Faraone SV, Doyle AE. The nature and heritability of attention-deficit/ hyperactivity disorder. Child Adolesc. Psychiatr. Clin. N. Am.10(2), 299–316, viii-ix (2001).
  • Brown GL, Hunt RD, Ebert MH, Bunne WE Jr, Kopin IJ. Plasma levels of D-amphetamine in hyperactive children. Serial behavior and motor responses. Psychopharmacology (Berl.)62(2), 133–140 (1979).
  • Swanson J, Gupta S, Guinta D et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin. Pharmacol. Ther.66(3), 295–305 (1999).
  • Sagvolden T, Johansen EB, Aase H, Russell VA. A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav. Brain Sci.28(3), 397–419; discussion 419–468 (2005).
  • Faraone SV, Perlis RH, Doyle AE et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol. Psychiatry57(11), 1313–1323 (2005).
  • Thapar A, Harrington R, Ross K, McGuffin P. Does the definition of ADHD affect heritability? J. Am. Acad. Child Adolesc. Psychiatry39(12), 1528–1536 (2000).
  • Coolidge FL, Thede LL, Young SE. Heritability and the comorbidity of attention deficit hyperactivity disorder with behavioral disorders and executive function deficits: a preliminary investigation. Dev. Neuropsychol.17(3), 273–287 (2000).
  • Martin N, Scourfield J, McGuffin P. Observer effects and heritability of childhood attention-deficit hyperactivity disorder symptoms. Br. J. Psychiatry180, 260–265 (2002).
  • Rietveld MJ, Hudziak JJ, Bartels M, van Beijsterveldt CE, Boomsma DI. Heritability of attention problems in children: I. cross-sectional results from a study of twins, age 3–12 years. Am. J. Med. Genet. B. Neuropsychiatr. Genet.117(1), 102–113 (2003).
  • Rietveld MJ, Hudziak JJ, Bartels M, van Beijsterveldt CE, Boomsma DI. Heritability of attention problems in children: longitudinal results from a study of twins, age 3 to 12. J. Child Psychol. Psychiatry45(3), 577–588 (2004).
  • Kuntsi J, Neale BM, Chen W, Faraone SV, Asherson P. The IMAGE project: methodological issues for the molecular genetic analysis of ADHD. Behav. Brain Funct.2, 27 (2006).
  • McGough JJ. Attention-deficit/hyperactivity disorder pharmacogenomics. Biol. Psychiatry57(11), 1367–1373 (2005).
  • Levy F. What do dopamine transporter and catechol-O-methyltransferase tell us about attention deficit-hyperactivity disorder? Pharmacogenomic implications. Aust. NZ J. Psychiatry41, 10–16 (2007).
  • Li D, Sham PC, Owen MJ, He L. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum. Mol. Genet.15(14), 2276–2284 (2006).
  • Brookes K, Xu X, Chen W et al. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol. Psychiatry11(10), 934–953 (2006).
  • Wang X, Zhong P, Yan Z. Dopamine D4 receptors modulate GABAergic signaling in pyramidal neurons of prefrontal cortex. J. Neurosci.22(21), 9185–9193 (2002).
  • Mill J, Caspi A, Williams BS et al. Prediction of heterogeneity in intelligence and adult prognosis by genetic polymorphisms in the dopamine system among children with attention-deficit/hyperactivity disorder: evidence from 2 birth cohorts. Arch. Gen. Psychiatry63(4), 462–469 (2006).
  • McGough J, McCracken J, Swanson J et al. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J. Am. Acad. Child Adolesc. Psychiatry45(11), 1314–1322 (2006).
  • Lowe N, Kirley A, Hawi Z et al. Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes. Am. J. Hum. Genet.74(2), 348–356 (2004).
  • Sotnikova TD, Beaulieu JM, Gainetdinov RR, Caron MG. Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. CNS Neurol. Disord. Drug Targets5(1), 45–56 (2006).
  • Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc. Psychiatr. Clin. N. Am.9(1), 77–97 (2000).
  • Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol. Psychiatry57(11), 1397–1409 (2005).
  • Drabant EM, Hariri AR, Meyer-Lindenberg A et al. Catechol-O-methyltransferase Val158Met genotype and neural mechanisms related to affective arousal and regulation. Arch. Gen. Psychiatry63(12), 1396–1406 (2006).
  • Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat. Rev. Neurosci.3(8), 617–628 (2002).
  • Mattay VS, Goldberg TE, Fera F et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl Acad. Sci. USA100(10), 6186–6191 (2003).
  • Wilens TE. Mechanism of action of agents used in attention-deficit/hyperactivity disorder. J. Clin. Psychiatry67(Suppl. 8), 32–38 (2006).
  • Easton N, Steward C, Marshall F, Fone K, Marsden C. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology52(2), 405–414 (2006).
  • Spencer T, Biederman J, Wilens T et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J. Am. Acad. Child Adolesc. Psychiatry35(4), 409–432 (1996).
  • Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res.36(2), 141–155 (1991).
  • Wilens TE, Biederman J, Spencer TJ, Prince J. Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review. J. Clin. Psychopharmacol.15(4), 270–279 (1995).
  • Pliszka SR. Non-stimulant treatment of attention-deficit/hyperactivity disorder. CNS Spectr.8(4), 253–258 (2003).
  • Swanson JM, Volkow ND. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci. Biobehav. Rev.27(7), 615–621 (2003).
  • Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy23(10), 1281–1299 (2003).
  • Wigal S, McGough J, Abikoff H et al. Behavioral effects of methylphenidate transdermal system in children with ADHD. Presented at: 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Toronto, Canada 18–23 October >2005.
  • Wilens T, Wigal S, Turnbow J, Kerkering J. Duration of effect of methylphenidate transdermal system after variable wear-time. Presented at: 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry. San Diego, CA, USA, 26 October 2006.
  • Glaser PE, Thomas TC, Joyce BM, Castellanos FX, Gerhardt GA. Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core. Psychopharmacology (Berl.)178(2–3), 250–258 (2005).
  • Biederman J, Krishnan S, Hodgkins P, Findling RL. Efficacy and safety of lisdexamfetamine (NRP104) in children aged 6 to 12 years with attention-deficit/hyperactivity disorder (ADHD). Presented at: 159th Annual Meeting of the American Psychiatric Association. Toronto, Canada, 20–25 May 2006.
  • Rotella D. Medicinal chemistry. Presented at: American Chemical Society – 230th National Meeting. Washington DC, USA, 28 August–1 September 2005.
  • Kroutil LA, Van Brunt DL, Herman-Stahl MA et al. Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend.84(2), 135–143 (2006).
  • Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics111(1), 179–185 (2003).
  • Barkley RA, Fischer M, Smallish L, Fletcher K. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics111(1), 97–109 (2003).
  • Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J. Clin. Psychiatry64(Suppl. 11), 3–8 (2003).
  • Greenhill LL. The science of stimulant abuse. Pediatr. Ann.35(8), 552–556 (2006).
  • Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J. Am. Acad. Child Adolesc. Psychiatry45(4), 408–414 (2006).
  • Jaffe SL. Failed attempts at intranasal abuse of Concerta. J. Am. Acad. Child Adolesc. Psychiatry41(1), 5 (2002).
  • Kollins SH, Rush CR, Pazzaglia PJ, Ali JA. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp. Clin. Psychopharmacol.6(4), 367–374 (1998).
  • Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am. J. Psychiatry160(11), 1909–1918 (2003).
  • Stoops WW, Glaser PE, Fillmore MT, Rush CR. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and D-amphetamine in stimulant abusing humans. J.Psychopharmacol.18(4), 534–543 (2004).
  • Spencer T, Rosenbaum J, Ciccone PE et al. A pet study examining pharmacokinetics, likability, and dopamine transorter receptor occupancy of methylphenidate formulations in adults. In: American College of Neuropsychopharmacology (ACNP) 43rd Annual Meeting. San Juan, Puerto Rico, Mexico 12–16 December 2004.
  • Spencer TJ, Biederman J, Ciccone PE et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am. J. Psychiatry163(3), 387–395 (2006).
  • Volkow ND, Ding YS, Fowler JS et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch. Gen. Psychiatry52(6), 456–463 (1995).
  • Volkow ND, Wang GJ, Fowler JS et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry155(10), 1325–1331 (1998).
  • Volkow ND, Wang GJ, Fowler JS et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse43(3), 181–187 (2002).
  • Jasinski J. Abuse liability studies of lisdexamfetamine dimesylate (NRP104). Presented at: 68th Annual Meeting of the College on Problems of Drug Dependence, CPDD. Scottsdale, AZ, USA, June 17–22 2006.
  • Greydanus DE, Sloane MA, Rappley MD. Psychopharmacology of ADHD in adolescents. Adolesc. Med.13(3), 599–624 (2002).
  • Swanson CJ, Perry KW, Koch-Krueger S et al. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology50(6), 755–760 (2006).
  • Faraone SV, Biederman J, Spencer T et al. Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug–placebo response curve analysis. Behav. Brain Funct.1, 16 (2005).
  • Weisler RH, Biederman J, Spencer TJ et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr.11(8), 625–639 (2006).
  • Snyder SH. New developments in brain chemistry: catecholamine metabolism and its relationship to the mechanism of action of psychotropic drugs. Am. J. Orthopsychiatry37, 864(1967).

Websites

  • Shire Bioequivalence Study Results Of SPD465, Investigational Drug For Adults With ADHD (2006). www.MedicalNewsToday.com
  • Faraone S, Biederman J, Spencer T, Aleardi M. Comparing the efficacy of medications using meta-analysis medscape General Medicine E Journal 8(4), 1–5 (2006). www.medscape.com

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.